表紙
市場調査レポート

世界のバイオテクノロジー企業の戦略:ライセンス契約・事業提携・企業合併・買収(M&A)の動向

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

発行 GlobalData 商品コード 260971
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
世界のバイオテクノロジー企業の戦略:ライセンス契約・事業提携・企業合併・買収(M&A)の動向 Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends
出版日: 2012年11月30日 ページ情報: 英文 75 Pages
概要

当レポートでは、全世界のバイオテクノロジー産業における資本取引(企業合併・買収(M&A)、ライセンシング、事業提携・パートナーシップ)の最新動向について分析し、これまでの取引動向・構造や促進要因、代表的な資本取引の詳細情報、今後の業界の方向性などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 過去の取引決定動向

  • 概要
  • 主な取引促進要因
    • 「特許の壁」
    • 研究開発(R&D)・イノベーションの不足
    • 新興国市場への戦略的移行
  • 全体的な取引状況
    • 取引の種類別の動向
    • 治療分野別の動向
  • バイオテクノロジー関連の資本取引状況

第4章 企業合併・買収(M&A)

  • 概要
  • GileadがPharmassetの111億米ドルでの買収を完了
  • GSKがHGSを36億米ドルで買収
  • Valeant Pharmaceuticalsが、Medicisを現金26億ドルで買収する合意を締結
  • AmgenがMicrometを11億米ドルで買収
  • AlexionがEnobia Pharmaの11億米ドルでの買収を完了
  • AlkermesがEDTより、Elanを10億米ドルで買収
  • CelgeneがAvila Therapeuticsを9億4700万米ドルで買収
  • Jazz PharmaceuticalsがEUSA Pharmaの6億7840万米ドルでの買収を完了
  • Jazz PharmaceuticalsがAzur Pharmaとの合併(5億7650万米ドル相当)を完了
  • Biogen IdecがStromedixの5億6250万米ドルでの買収を終了

第5章 ライセンス取引

  • 概要
  • AcordaがWatson Pharmaと販売ライセンス契約を調印
  • BaxterがOnconova Therapeuticsとの間で、5億6500万米ドル相当の契約を締結
  • ExelixisとMerckが、"PI3K-δ"に関するライセンス契約を締結
  • MomentaがBaxterと、次世代の生物薬剤に関するライセンス契約を締結
  • NektarとRocheが、製造ライセンス契約を締結

第6章 事業提携/パートナーシップ

  • 概要
  • AblynxがBoehringer Ingelheimと、ナノボディ関連契約の延長に合意
  • NovartisがUniversity of Pennsylvaniaとのパートナーシップに調印
  • IronwoodがBionomicsとの事業提携契約を締結
  • J&J's Janssen Biotech Unitが、Genmabとの事業提携契約に調印
  • PfizerとMylan Pharmaceuticalsが、ジェネリック医薬品製造に関するパートナーシップを締結

第7章 今後の見通し

  • 概要
  • 取引決定の動向
    • 大手医薬品企業と同様に、バイオテクノロジー企業も世界的なプレゼンスの強化を追及する
    • 「小規模」バイオテクノロジー企業が「大規模」バイオテクノロジー企業への飛躍を目指して、企業合併・買収(M&A)活動を続ける
    • バイオテクノロジー企業の取引決定が、大手製薬企業にとっての知的財産(IP)の供給源であり続ける

第8章 付録

図表一覧

目次
Product Code: GDHC001MAL

Summary

GlobalData's Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends report analyzes 20 strategic deals struck by leading and promising biotech companies. The terms and strategic drivers of these deals are analyzed based on acquisition costs, strategic fit, potential revenues, competitive advantage as well as other measures to illustrate the strategies different companies are currently using to gain market share, increase shareholder value and bring innovative and life-saving products to the booming global pharmaceuticals market. This report is an essential source of information and analysis on global strategic deals involving the top players in the global pharmaceuticals market.

Scope

  • The report provides full details of 20 significant deals from Q3 2011 to Q3 2012 involving promising biotech companies including deal terms and payment structure.
  • The report provides analysis of the key drivers, trends, and strategies behind deals undertaken by biotech companies across important geographic regions including the US, EU, Asia-Pacific, Brazil, Russia, India, China, and other emerging markets.
  • The report covers the six major therapy areas of cardiovascular disease, central nervous system (CNS), diabetes and metabolic, immunology, oncology, and respiratory.
  • The report contains expert insights on the corporate strategies of emerging biotech companies seeking competitive advantage in the pharmaceuticals marketplace.

Reasons to buy

  • Analyze and emulate the strategies that promising biotech companies are using to gain market share in the increasingly competitive global pharmaceuticals market.
  • Understand the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
  • Identify potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships.
  • Organize your sales and marketing efforts by identifying the business regions and segments to maximize opportunities for consolidation, investment and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
    • 2.1.1. Key Questions Answered
    • 2.1.2. Key Benefits
  • 2.2. Upcoming Related Reports
  • 2.3. Recently published reports:

3. Historical Dealmaking Trends

  • 3.1. Overview
  • 3.2. Leading Deal Drivers
    • 3.2.1. The Patent Cliff
    • 3.2.2. Lack of R&D Innovation
    • 3.2.3. Strategic Shift to Emerging Markets
  • 3.3. Overall Deals in Review
    • 3.3.1. Review by Deal Type
    • 3.3.2. Review by Therapy Area
  • 3.4. Biotech Deals in Review

4. Mergers and Acquisitions

  • 4.1. Overview
  • 4.2. Gilead Completes $11.1 Billion Acquisition of Pharmasset
    • 4.2.1. Deal Description
    • 4.2.2. Deal Analysis
  • 4.3. GSK Acquires HGS in $3.6 Billion Deal
    • 4.3.1. Deal Description
    • 4.3.2. Deal Analysis
  • 4.4. Valeant Pharmaceuticals Agrees $2.6 Billion Cash Deal for Medicis Acquisition
    • 4.4.1. Deal Description
    • 4.4.2. Deal Analysis
  • 4.5. Amgen Acquires Micromet in $1.1 Billion Deal
    • 4.5.1. Deal Description
    • 4.5.2. Deal Analysis
  • 4.6. Alexion Completes Acquisition of Enobia Pharma in $1.1 Billion Deal
    • 4.6.1. Deal Description
    • 4.6.2. Deal Analysis
  • 4.7. Alkermes Acquires EDT from Elan in $1 Billion Deal
    • 4.7.1. Deal Description
    • 4.7.2. Deal Analysis
  • 4.8. Celgene Acquires Avila Therapeutics in $947.0m Deal
    • 4.8.1. Deal Description
    • 4.8.2. Deal Analysis
  • 4.9. Jazz Pharmaceuticals Completes $678.4m Acquisition of EUSA Pharma
    • 4.9.1. Deal Description
    • 4.9.2. Deal Analysis
  • 4.10. Jazz Pharmaceuticals Completes $576.5m Merger with Azur Pharma
    • 4.10.1. Deal Description
    • 4.10.2. Deal Analysis
  • 4.11. Biogen Idec Closes $562.5m Deal for the Acquisition of Stromedix
    • 4.11.1. Deal Description
    • 4.11.2. Deal Analysis

5. Licensing Deals

  • 5.1. Overview
  • 5.2. Acorda Signs Marketing License Agreement with Watson Pharma
    • 5.2.1. Deal Description
    • 5.2.2. Deal Analysis
  • 5.3. Baxter Enters Potential $565.0m Deal with Onconova Therapeutics
    • 5.3.1. Deal Description
    • 5.3.2. Deal Analysis
  • 5.4. Exelixis and Merck Involved in "PI3K-δ" Licensing Deal
    • 5.4.1. Deal Description
    • 5.4.2. Deal Analysis
  • 5.5. Momenta Enters into Follow-On Biologics Licensing Agreement with Baxter
    • 5.5.1. Deal Description
    • 5.5.2. Deal Analysis
  • 5.6. Nektar and Roche Involved in Manufacturing License Deal
    • 5.6.1. Deal Description
    • 5.6.2. Deal Analysis

6. Collaborations/Partnerships

  • 6.1. Overview
  • 6.2. Ablynx Extends Nanobody Deal with Boehringer Ingelheim
    • 6.2.1. Deal Description
    • 6.2.2. Deal Analysis
  • 6.3. Novartis Pens Partnership with the University of Pennsylvania
    • 6.3.1. Deal Description
    • 6.3.2. Deal Analysis
  • 6.4. Ironwood Enters into Collaboration Agreement with Bionomics
    • 6.4.1. Deal Description
    • 6.4.2. Deal Analysis
  • 6.5. J&J's Janssen Biotech Unit Inks Collaboration Deal with Genmab
    • 6.5.1. Deal Description
    • 6.5.2. Deal Analysis
  • 6.6. Pfizer and Mylan Pharmaceuticals Enter into Generics Manufacturing Partnership
    • 6.6.1. Deal Description
    • 6.6.2. Deal Analysis

7. Future Outlook

  • 7.1. Overview
  • 7.2. Dealmaking Trends
    • 7.2.1. Biotech companies, like Big Pharma, will pursue deals to increase their global presence
    • 7.2.2. "Small Biotech" will continue to engage in M&A in attempts to make the leap to "Big Biotech"
    • 7.2.3. Biotech deal-making will remain a source of IP for Big Pharma

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Research Methodology
    • 8.3.1. Coverage
    • 8.3.2. Secondary Research
    • 8.3.3. Expert Panel Validation
  • 8.4. About the Authors
    • 8.4.1. Analyst
    • 8.4.2. Global Head of Healthcare Research and Consulting
  • 8.5. About the Industry Dynamics Team
  • 8.6. GlobalData
  • 8.7. Contact Us
  • 8.8. Disclosure Information
  • 8.9. Disclaimer

List of Tables

  • Table 1: Recent and Upcoming US Patent Expirations
  • Table 2: M&A Deals, 3Q11-3Q12
  • Table 3: Gilead's Acquisition of Pharmasset
  • Table 4: GSK's Acquisition of HGS
  • Table 5: Valeant Pharmaceutical's Acquisition of Medicis
  • Table 6: Amgen's Acquisition of Micromet
  • Table 7: Alexion's Acquisition of Enobia Pharma
  • Table 8: Alkermes' Acquisition of EDT from Elan
  • Table 9: Celgene's Acquisition of Avila Therapeutics
  • Table 10: Jazz Pharmaceuticals' Acquisition of EUSA Pharma
  • Table 11: Jazz Pharmaceuticals' Merger with Azur Pharma
  • Table 12: Biogen's Acquisition of Stromedix
  • Table 13: Acorda's Licensing Agreement with Watson Pharma
  • Table 14: Acorda's Licensing Agreement with Watson Pharma
  • Table 15: Exelixis' Licensing Agreement with Merck
  • Table 16: Momenta's Licensing Agreement with Baxter
  • Table 17: Nektar's Licensing Agreement with Roche
  • Table 18: Ablynx's Collaboration with BI
  • Table 19: Novartis' Collaboration with the University of Pennsylvania
  • Table 20: Ironwood's Collaboration with Bionomics
  • Table 21: Janssen's Collaboration with Genmab
  • Table 22: Pfizer's Collaboration with the Mylan Pharmaceuticals

List of Figures

  • Figure 1: FDA Approvals of NDAs and BLAs, FY2005-FY2011
  • Figure 2: Deal Analysis - Total Number of Deals and Deal Values ($m), 3Q07-2Q12
  • Figure 3: Deal Analysis - Deals Distribution, 3Q07-2Q12
  • Figure 4: Top 10 Therapeutic Areas by number and Value of Deals, 3Q11-2Q12
  • Figure 5: Biotech Deals Breakdown by Type, Q3 2011-Q3 2012
  • Figure 6: M&A Spending, Q3 2011-Q3 2012 ($m)
  • Figure 7: Xyrem Sales as Percentage of Jazz Pharmaceuticals' Annual Revenues, 2005-2011 ($m)
  • Figure 8: Licensing Deals1, Q3 2011-Q3 2012
  • Figure 9: Breakdown of Collaboration deals, Q3 2011-Q3 2012 ($m)
  • Figure 10: Pfizer:Emerging Markets Revenues as a Percentage of Annual Revenues, 2006-2011
Back to Top